Xeris Biopharma Statistics Share Statistics Xeris Biopharma has 161.48M
shares outstanding. The number of shares has increased by 8.32%
in one year.
Shares Outstanding 161.48M Shares Change (YoY) 8.32% Shares Change (QoQ) 0.83% Owned by Institutions (%) 58.06% Shares Floating 154.25M Failed to Deliver (FTD) Shares 567 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 16.24M, so 10.06% of the outstanding
shares have been sold short.
Short Interest 16.24M Short % of Shares Out 10.06% Short % of Float 10.46% Short Ratio (days to cover) 10
Valuation Ratios The PE ratio is -9.07 and the forward
PE ratio is 33.24.
Xeris Biopharma's PEG ratio is
0.51.
PE Ratio -9.07 Forward PE 33.24 PS Ratio 2.45 Forward PS 3.8 PB Ratio -16.8 P/FCF Ratio -13.15 PEG Ratio 0.51
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Xeris Biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.67,
with a Debt / Equity ratio of -9.17.
Current Ratio 1.67 Quick Ratio 1.19 Debt / Equity -9.17 Debt / EBITDA -19.4 Debt / FCF -7.17 Interest Coverage -1.01
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $515.41K Profits Per Employee $-139.18K Employee Count 394 Asset Turnover 0.63 Inventory Turnover 0.76
Taxes Income Tax -2.27M Effective Tax Rate 3.97%
Stock Price Statistics The stock price has increased by 175.17% in the
last 52 weeks. The beta is 0.9, so Xeris Biopharma's
price volatility has been higher than the market average.
Beta 0.9 52-Week Price Change 175.17% 50-Day Moving Average 7.27 200-Day Moving Average 5.07 Relative Strength Index (RSI) 59.59 Average Volume (20 Days) 2,430,268
Income Statement In the last 12 months, Xeris Biopharma had revenue of 203.07M
and earned -54.84M
in profits. Earnings per share was -0.37.
Revenue 203.07M Gross Profit 166.24M Operating Income -33.65M Net Income -54.84M EBITDA -13.99M EBIT -26.62M Earnings Per Share (EPS) -0.37
Full Income Statement Balance Sheet The company has 71.62M in cash and 271.45M in
debt, giving a net cash position of -199.83M.
Cash & Cash Equivalents 71.62M Total Debt 271.45M Net Cash -199.83M Retained Earnings -671.86M Total Assets 334.69M Working Capital 90.41M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -36.98M
and capital expenditures -868K, giving a free cash flow of -37.85M.
Operating Cash Flow -36.98M Capital Expenditures -868K Free Cash Flow -37.85M FCF Per Share -0.26
Full Cash Flow Statement Margins Gross margin is 81.86%, with operating and profit margins of -16.57% and -27%.
Gross Margin 81.86% Operating Margin -16.57% Pretax Margin -28.12% Profit Margin -27% EBITDA Margin -6.89% EBIT Margin -16.57% FCF Margin -18.64%
